Clinuvel Pharmaceuticals

Biotechnology Research • Melbourne, Victoria, Australia • 51-100 Employees

Company overview

Headquarters	Level 22, 535 Bourke Street, Melbourne, Victoria 3000, AU
Phone number	+61396604900
Website	clinuvel.com
NAICS	541714
SIC	283
Keywords	Biotechnology, Pharmaceutical, Rare Diseases, Drug Development, Drug Commercialisation, Photomedicine, Erythropoietic Protoporphyria, Photocare, Photoprotection
Founded	2001
Employees	51-100
Socials

Key Contacts at Clinuvel Pharmaceuticals

Marga Arrom Bibiloni

Global Director - Brand Strategy & Creative

Sue Smith

Non Executive Director

Emilie Rodenburger

Director Global Clinical Affairs

Philippe Wolgen

Chief Executive Officer

Clinuvel Pharmaceuticals Email Formats

Clinuvel Pharmaceuticals uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@clinuvel.com), used 58.7% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@clinuvel.com	58.7%
{first initial}.{last name}	j.doe@clinuvel.com	39.7%
{first initial}{second initial}.{last name}	jo.doe@clinuvel.com	1.6%

About Clinuvel Pharmaceuticals

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to http://www.clinuvel.com. SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD

Clinuvel Pharmaceuticals revenue & valuation

Annual revenue	$58,900,000
Revenue per employee	$692,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$188,200,000
Total funding	No funding

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Senior

Employees by Department

Clinuvel Pharmaceuticals has 38 employees across 12 departments.

Departments

Number of employees

Funding Data

Clinuvel Pharmaceuticals has never raised funding before.

Clinuvel Pharmaceuticals Tech Stack

Discover the technologies and tools that power Clinuvel Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

Twitter Emoji

Font scripts

reCAPTCHA

Security

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

Nginx

Reverse proxies

Slider Revolution

Photo galleries

Contact Form 7

Form builders

PHP

Programming languages

Open Graph

Miscellaneous

WordPress

Blogs

jQuery Migrate

JavaScript libraries

Frequently asked questions

Clinuvel Pharmaceuticals is located in Melbourne, Victoria, AU.

You can reach Clinuvel Pharmaceuticals at +61396604900.

Clinuvel Pharmaceuticals was founded in 2001, making it 25 years old. The company has established itself as a significant player in its industry over this time.

Clinuvel Pharmaceuticals has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.